The European Commission on 28 May proposed a so-called ‘export manufacturing waiver’ to Supplementary Protection Certificates.

“The Commission is proposing a targeted adjustment to intellectual property rules to help Europe’s pharmaceutical companies tap into fast-growing global markets and foster jobs, growth and investments in the EU.”

A copy of the EC press release can be read here.